ArticleBioMedicine2026
Evaluation of Bai-Zhu (
Article in BioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bai-Zhu ( Methods: A tetrazolium-based semiautomated colorimetric (MTT) assay was used to assess cell viability. Western blotting was performed to evaluate protein expression. Quantitative RT-PCR was employed to measure the relative expression levels of selected genes. A Matrigel invasion assay was used to assess the invasive capacity of cancer cells. Results: Water extracts of Bai-Zhu or formulae containing Bai-Zhu increased the expression of metastasis-related proteins Zeb1 and Slug in breast cancer cells. Moreover, these formulae further enhanced Zeb1 and Slug expression when combined with the chemotherapeutic drug doxorubicin. Matrigel invasion assays confirmed that these treatments promoted the invasive activity of breast cancer cells. Conclusions: The use of Bai-Zhu-containing formulae should be carefully evaluated, particularly in cancer patients who use them as complementary or alternative treatments, due to their potential to promote tumor metastasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.